Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Raises $135M in Series D Financing Round

NEW YORK — Single-cell proteomics firm IsoPlexis said today it has closed a $135 million Series D financing.

The round consists of $85 million in equity securities and a $50 million credit facility and was led by Perceptive Advisors, with participation from other new investors including Ally Bridge Group, funds and accounts managed by BlackRock, as well as other existing investors.

The Branford, Connecticut-based company said it will use the proceeds to expand its global commercial and R&D teams, increase operational capacity to meet growing demand, and accelerate product development.

IsoPlexis' IsoLight and IsoSpark systems use microchips featuring arrays of thousands of microchambers that isolate individual cells from samples of interest. These chambers are then sealed with a slide patterned with groups of antibodies in a number of different spatially isolated lines. This allows the researchers to identify proteins based on the color of fluorescence produced upon binding and the location on the slide where the binding event occurs. In this way, they can multiplex well beyond the levels allowed by fluorescence readout alone.

"With more than 100 systems placed and a strong team of over 200 employees, we have laid an incredibly strong foundation for future growth at the convergence of single-cell biology, proteomics, and multi-omics," IsoPlexis Co-founder and CEO Sean MacKay said in a statement. "We look forward to deploying this capital to accelerate our commercial efforts as we work to leverage our powerful biology to impact the future of advanced medicines."

"IsoPlexis' unique technology is giving researchers this access through the convergence of dynamic proteomics and single cell biology," said Michael Altman, managing director at Perceptive Advisors. "We are delighted to support IsoPlexis and their vision to accelerate the development of personalized therapeutics to significantly impact human health."